[Back to Our Trials]
Luminosity: Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Condition: Non-small Cell Lung Cancer
Go To Trial Homepage
For more information you may call clinical trials department directly at 732-390-7750 or email us at
astera.clinicaltrial@asterahealthcare.org
.